Salmonella

一种预防幽门螺杆菌感染的组合物及制备方法和应用

Resumen de: CN122351451A

本发明提供了一种预防幽门螺杆菌感染的组合物及制备方法和应用。所述组合物包括外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液；所述外膜囊泡混合物由沙门菌突变株QS0074的外膜囊泡和大肠杆菌E. coli Nissle 1917的外膜囊泡按照重量比2:1组成；所述外膜囊泡混合物和嗜黏蛋白阿克曼氏菌菌液的重量体积比为1mg:1mL。本发明所得组合物在攻毒试验中，显著优于对照组，具有高效的预防幽门螺杆菌感染的效果。同时，本发明的组合物各组分之间在诱导小鼠产生分泌性IgA水平和分泌性IgA水平以及诱导小鼠产生抵抗幽门螺杆菌感染能力方面，均产生了明显的协同作用，具有良好的应用前景。

MICROBIALS FOR SALMONELLA INHIBITION

Resumen de: WO2026148245A1

The present disclosure relates to microbials for use in E. coli, Salmonella, Enterococcus and/or Clostridium inhibition in animals and their environment. More particularly, the present disclosure relates to isolated Bacillus strains MDG-844 (NRRL No. B-68469), MDG-UF7 (NRRL No. B-68470), MDG-UC25 (NRRL No. B-68471), and MDG-I60 (NRRL No. B-68472), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use.

PORCINE INTERFERON-LIKE RECOMBINANT PROTEIN AND USE THEREOF

Resumen de: US20260191946A1

This invention relates to the field of biomedicine and specifically to a porcine interferon-like recombinant protein and its applications. By constructing and screening a PoIFN-α DNA shuffling bacterial library, a highly active recombinant protein Porferon was obtained. Porferon exhibits potent anti-infective activity against a broad range of porcine pathogens, including viruses, bacteria, and parasites. Its biological activity is significantly superior to that of natural porcine interferon. As such, Porferon can be used in the development of therapeutics for the prevention or treatment of infectious diseases in pigs, offering a novel and effective solution for clinical applications in veterinary medicine.

LIVER DISEASE TREATMENTS USING ATTENUATED STRAINS OF SALMONELLA TYPHIMURIUM

Resumen de: US20260183346A1

0000 The composition and methods of treatment disclosed or contemplated herein include compositions and methods of treatment for liver-related diseases. The overall treatment strategy would involve the identification of a target protein or receptor within the liver that is responsible for ongoing liver injury. The strain of orally administered Salmonella Typhimurium that colonizes the liver would be engineered to secrete a particular protein or nanobody that would stop and/or reverse the progressive hepatic disease

STABLE SALMONELLA VACCINE FORMULATIONS

Resumen de: WO2025042889A1

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided.

細菌感染に対する免疫を生成するための組成物および方法

Resumen de: WO2024254147A1

The present disclosure relates, in part, to a polypeptide of formula (I), or a salt or solvate thereof, and a vaccine composition thereof further comprising at least one pharmaceutically acceptable excipient. The present disclosure further relates to isolated mRNA and/or isolated polynucleotides encoding the polypeptide of formula (I), vectors and/or LNPs comprising the same, and pharmaceutical compositions thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a bacterial infection, and/or generating immunity to infection by one or more pathogenic bacteria, in a subject in need thereof, the method comprising administering to the subject at least one composition of the present disclosure. In certain embodiments, the bacterial infection is a urinary tract infection, sepsis (e.g, neonatal sepsis), or pneumonia.

鞭毛蛋白高变区H作为分子内佐剂在制备疫苗中的应用

Resumen de: CN122297663A

本发明涉及生物蛋白应用技术领域，公开了鞭毛蛋白高变区H作为分子内佐剂在制备疫苗中的应用。鞭毛蛋白高变区H的氨基酸序列如SEQ ID NO.3所示，编码鞭毛蛋白高变区H的基因的核苷酸序列如SEQ ID NO.4所示。本发明还公开了含有编码鞭毛蛋白高变区H的基因的表达盒、重组载体、重组细胞或重组菌。本发明采用上述的鞭毛蛋白高变区H作为分子内佐剂在制备疫苗中的应用，本发明将鞭毛蛋白高变区H与抗原表位相连接得到融合蛋白，与现有技术相比，融合蛋白的可溶性和活性得到提高，同时本发明克服了现有大肠杆菌表达系统中包涵体的表达形式，后期不需要重新折叠组装，精简了疫苗制备工艺。

BACTERIAL VESICLES FOR RADIOTHERAPEUTIC DELIVERY OF BORON

Resumen de: WO2026133273A1

Intact bacterial vesicles are highly effective for in vivo delivery of boron for radiotherapeutic purposes, as in boron neutron capture therapy. A compound comprising a boron isotope, such as boron-10 or boron-11, can be joined chemically to a fluorescent moiety to produce a molecule that can be loaded stably into bacterial vesicles, which when coated with an appropriately targeting bispecific antibody can deliver boron specifically into tumor cells in an amount enabling boron-mediated radiotherapy that eliminates tumor cells with minimal damage to adjacent normal cells.

- Recombinant Expression Vector for Secretion of Interferon- and Attenuated Salmonella Transformed Therewith

Resumen de: WO2024025312A1

The present invention relates to a recombinant expression vector for secretion of IFN-β proteins and an attenuated Salmonella strain transformed by means of same, and provides: a recombinant expression vector comprising flgM genes, IFN-β genes, and flhDC genes; an attenuated Salmonella strain transformed by means of same; and a pharmaceutical composition for cancer treatment comprising the attenuated Salmonella strain as an active ingredient.

一种Ulp1酶双抗夹心ELISA试剂盒及应用

Resumen de: CN120992924A

The invention belongs to the technical field of Ultrap1 enzyme quantitative detection, and particularly relates to an Ultrap1 enzyme double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) kit and application. Comprising an elisa plate coated with an anti-Ultrap1 enzyme mouse monoclonal antibody, an anti-Ultrap1 enzyme rabbit polyclonal antibody, an HRP-labeled goat anti-rabbit antibody, a diluent, a cleaning solution, a confining solution, a developing solution and a stop solution. According to the present invention, the complex of the Ulp1 enzyme and the SUMO tag protein is adopted as the immunogen to simultaneously immunize mice and New Zealand rabbits so as to prepare different species of the good affinity Ulp1 enzyme antibodies, and then the optimal reaction condition is further screened to develop the stable double-antibody sandwich ELISA detection kit with characteristics of high specificity and strong sensitivity, the defects in the prior art can be effectively overcome.

一种htrA基因敲除的减毒沙门氏菌重组工程菌株及其应用

Resumen de: CN122214226A

本发明公开了一种htrA基因敲除的减毒沙门氏菌重组工程菌株及其应用，对减毒沙门氏菌VNP20009进行基因组遗传改造，将基因组中的htrA基因敲除，获得ΔhtrA‑VNP菌株。通过回补性表达带有/不带有信号肽的HtrA蛋白，首次证实信号肽对于HtrA蛋白的功能发挥至关重要。无信号肽的htrA基因回补菌株与ΔhtrA‑VNP菌株生物学表型无显著差异。本发明所述的表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，HtrA蛋白通过调控细菌胞外多糖水平，一方面影响菌株的免疫原性与抗癌效果，另一方面影响菌株对抗巨噬细胞的杀伤效果，进而影响细菌在体内的分布特性。本发明基于htrA基因活性作用模式，建立了瘤内时空特异性启动表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，实现更高效、安全与精准的活体微生物抗肿瘤治疗。

用于对饮食品样本、环境样本或生物体样本中的肠杆菌科细菌的有无和/或存在量进行检测的方法和试剂盒

Resumen de: EP4279503A1

0001 Provided is a method that enables the presence and/or amount of bacteria of Enterobacteriaceae in a food/drink sample, an environmental sample, or a biological sample to be detected easily and efficiently in a short amount of time. Said method includes a step for simultaneously detecting, on the basis of an antigen-antibody reaction, the presence and/or amount of bacteria of Enterobacteriaceae of at least two different genera in a sample.

一种细菌复合疫苗与顺铂的协同抗肿瘤组合及其应用

Resumen de: CN122182751A

本发明公开了一种细菌复合疫苗与顺铂的协同抗肿瘤组合及其应用，属于肿瘤药物制备技术领域。所述抗肿瘤组合包括以下成份：细菌复合疫苗和顺铂。本发明通过细菌复合疫苗和顺铂的协同配合，在对肿瘤模型的试验小鼠进行治疗时发现，相较于单一的细菌复合疫苗治疗组和单一的顺铂治疗组，二者的协同用药对肿瘤细胞增殖的抑制作用显著上升，具有良好的抗肿瘤效果。

DNA CONSTRUCT FOR EXPRESSING SIGNALING SUBSTANCE FOR CANCER TREATMENT, AND CANCER TREATMENT METHOD USING SAME

Resumen de: AU2024374864A1

Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.

COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER USING BACTERIA

Resumen de: US20260158079A1

Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.

Monoclonal antibody specific to Vibrio cholerae or Salmonella typhi and simultaneous rapid diagnostic kit using the same

Resumen de: KR20260084896A

본 발명은 콜레라균 또는 장티푸스균에 특이적인 단일클론 항체 및 이를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것으로, 보다 상세하게는 서열번호 2, 서열번호 4, 서열번호 6 또는 서열번호 8의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 콜레라균(Vibrio cholerae)에 특이적으로 결합하는 단일클론 항체 및 서열번호 10 또는 서열번호 12의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 살모넬라 티피(Salmonella typhi)에 특이적으로 결합하는 단일클론 항체를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것이다.

Methods of treatment of infections using bacteria

Resumen de: AU2026203814A1

The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non- viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines. ay a y

METHODS AND SYSTEMS FOR THE RAPID DETECTION OF LISTERIA USING INFECTIOUS AGENTS

Resumen de: MX2026005882A

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF

Resumen de: US20260144857A1

Technologies for the prevention and/or treatment of Shigella infections.

NANOBODY FOR DETECTING ESCHERICHIA COLI O157:H7 AND PREPARATION METHOD THEREFOR

Resumen de: WO2026108702A1

Disclosed in the present invention are a nanobody for detecting Escherichia coli O157:H7 and a preparation method therefor. The present invention aims to provide a nanobody for detecting Escherichia coli O157:H7 with high detection accuracy and a simple acquisition method. The amino acid sequence of the nanobody is set forth in SEQ ID NOs. 1-3. The present invention belongs to the technical field of biopharmaceuticals.

SYSTEM AND METHOD FOR DETECTING, ENUMERATING, OR EXTRACTING MICROORGANISMS IN A SAMPLE

Resumen de: US20260146994A1

A system and method for detecting, enumerating, or extracting microorganisms in a sample is disclosed. Target microorganisms, such as Salmonella bacteria, may be of interest. Magnetic beads may be bound to the target microorganisms. After which, the bead-bound cells may be isolated. For example, a magnetic field may be applied in order to separate the target cells (with the magnetic beads attached thereto) and move then to a predetermined section of the well. Agar, or other immobilizing agent, may be added to the wells in order to immobilize the target cells. After which, the target cells are incubated and periodically analyzed to determine whether the target cells are growing, thereby indicating that the microorganisms are contained within the well.

IMMUNOGENIC COMPOSITION

Resumen de: WO2025021695A1

The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.

VACCINE

Resumen de: WO2025021710A1

The present invention relates to immunogenic compositions comprising S. enterica serovar Paratyphi A outer membrane vesicles (OMVs), vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions. The present invention also relates to an S. Paratyphi A bacterium comprising modified lipid A.

一种表达微管抑制蛋白的肿瘤靶向工程菌及其应用

Resumen de: CN122081185A

本发明属于生物医药技术领域，公开了一种用于肿瘤原位表达微管抑制蛋白的工程化细菌及其应用。通过将微管抑制蛋白基因构建至表达载体，最终转入细菌，形成工程菌。该工程菌能靶向定植于肿瘤微环境，表达微管抑制蛋白，有效抑制肿瘤细胞，显著抑制实体瘤生长，且安全性优良。

医薬組成物及びその製造方法と使用

Nº publicación: JP2026516846A 26/05/2026

Solicitante:

普公生物科技（杭州）有限公司

Resumen de: CN118846069A

The invention relates to the field of medicine, in particular to a pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises a first effective component, a second effective component and a pharmaceutically acceptable carrier or auxiliary material, the microbial agent comprises any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or paratyphoid bacillus, and the second effective component comprises polyinosinic acid, polycytidylic acid and vitamin. The pharmaceutical composition belongs to artificial active immunotherapy aiming at tumors, can'stimulate 'the whole immune system, enables the therapy of activating the human immune system by bacteria to kill cancer cells to be quite stable and reliable, can remarkably save and prolong the life of cancer patients, has extremely high safety and extremely small toxic and side effects, and is suitable for clinical application. And the preparation cost is low.